Live Breaking News & Updates on Urologic Cancers At Duke University

PHILADELPHIA – Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research , a journal of the American Association for Cancer Research. ....

United States , Andrew Armstrong , Genentech Roche , Johns Hopkins University , Urologic Cancers At Duke University , Molecular Cancer Research , University Of Chicago , Constellation Pharmaceuticals , Bristol Myers Squibb , Duke Cancer Institute Center , National Comprehensive Cancer Network , National Institutes Of Health , Global Treatment Sciences Challenge Award , American Association For Cancer Research , Weill Medical College Of Cornell University , Prostate Cancer Foundation , Duke University , Memorial Sloan Kettering Cancer Center , American Association , Urologic Cancers , National Institutes , Weill Medical College , Cornell University , Cancer Research , Prostate Cancer , Abiraterone Acetate ,